PharmaMar
PharmaMar is a Spanish pharmaceutical company headquartered in Colmenar Viejo, Madrid, Spain. Founded in 1986 as a subsidiary of Zeltia, it absorbed its parent company and all its subsidiaries in a reverse merger takeover in 2015. The company is a component of the Madrid Stock Exchange General Index (IGBM) and the IBEX 35 since 2020, after being part of the Ibex Small Cap stock market index.

PharmaMar engages in the research and development, manufacturing and marketing of pharmaceutical drugs derived from marine-related resources for the treatment of diverse types of cancer and Alzheimer. Through its subsidiary Genomica, PharmaMar has also developed molecular testing procedures for several infectious diseases, among them COVID-19, and it has become a leader in genetic analysis and paternity testing in the Spanish market. Its subsidiary Sylentis develops therapies based in gene silencing techniques like RNA interference.
Q507443
pharmaceutical company
Concept
Q55441
Zeltia
Concept
Q1020015
reverse merger takeover
Concept
Q3493004
Madrid Stock Exchange General Index
MEDIA
Q938032
IBEX 35
MEDIA
Q276099
research and development
Concept
Q12140
pharmaceutical drugs
Concept
Q11081
Alzheimer
Concept
Q16257937
molecular testing
Concept
Q166231
infectious diseases
Concept
Q84263196
COVID-19
Concept
Q1431332
gene silencing
UNK
Q201993
RNA interference
Concept
Q96399023
PharmaMar
ORG
Q96399023
PharmaMar
ORG
Q96399023
PharmaMar
ORG
1986-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1986
DATE
2015-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2015
DATE
2020-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2020
DATE
+35^^http://www.w3.org/2001/XMLSchema#decimal
35
NUMBER
-19^^http://www.w3.org/2001/XMLSchema#decimal
-19
NUMBER
inception